Yes. Patients with type 2 diabetes benefit from case management, as evidenced by decreased glycated hemoglobin (HbA1c). The improvement in HbA1c appeared larger when case managers could make changes in medications independently and multidisciplinary teams were used (strength of recommendation [SOR]: C, 2 meta-analyses of randomized controlled trials [RCTs] with consistent disease-oriented findings). Patients with type 1 diabetes who have case management and “intense control” experience fewer cardiovascular events and decreased retinopathy and clinical neuropathy (SOR: B, 1 large, good-quality RCT).
The many definitions used to describe case management present a challenge in summarizing its effect.1,2 A Cochrane review of case management by a “diabetes specialist nurse/nurse case manager” included 6 trials and 1382 patients with either type 1 or type 2 diabetes. It revealed a short-term benefit (lower HbA1c) in only 1 trial at 6 months and no difference in HbA1c or improvement in quality of life in any trial at 12 months.3
However, a review of 66 RCTs of case management for type 2 diabetes found a mean reduction in HbA1c of 0.52% (95% confidence interval [CI], 0.31-0.73) after adjusting for study size (smaller studies tended to report larger changes) and whether or not patients were “poorly controlled” at baseline (studies with higher HbA1c levels at baseline also reported larger effects).1 The most striking HbA1c reduction occurred when case managers could make medication adjustments without physician approval (change in HbA1c=0.80%; 95% CI, 0.51-1.10). Moreover, using a multidisciplinary team reduced HbA1c by 0.37% more than interventions without such a team (95% CI, 0.16-0.58).
The authors of an earlier review of 15 case management studies for type 2 diabetes concluded that case management alone was beneficial, resulting in an HbA1c improvement of 0.40% (interquartile range=0.46-0.65).4 However, they further noted that studies that showed case management to be effective also involved disease management or included additional interventions such as education, reminders, or other supports.
But studies don’t always show robust outcomes
Outcomes in other studies often aren’t as robust. In the year-long Informatics for Diabetes Education and Telemedicine (IDEATel) project,5 for example, nurse case managers supervised by diabetologists and working with primary care physicians were able to direct care based on pre-established algorithms. Those in the intervention group with a baseline HbA1c >7 had an HbA1c reduction of 0.32% and small but statistically significant reductions in blood pressure (3.4 mm Hg systolic and 1.9 mm Hg diastolic) and low-density lipoprotein (9.5 mg/dL).